AbbVie will obtain an option to licence exclusive global intellectual property rights to various novel candidates from Dragonfly under the deal. Credit: © AbbVie Inc. All rights reserved.

Dragonfly Therapeutics and AbbVie have expanded their research partnership for the discovery and development of the former’s novel immunotherapies for new targets in fibrotic and autoimmune diseases. 

In January last year, AbbVie had licenced its first Tri-specific NK cell Engager Therapy (TriNKET) drug candidate from Dragonfly. 

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The licencing is part of a multi-target partnership signed by the companies in November 2019.

Under the latest deal, AbbVie will obtain an option to licence exclusive global intellectual property rights to various new candidates from Dragonfly.

These candidates will be developed leveraging the TriNKET technology platform of Dragonfly. 

See Also:

As per the collaboration, Dragonfly is entitled to receive an upfront payment, milestone payments based on success in the future and royalty payments from AbbVie.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

AbbVie Discovery Research vice-president and global head Dr Jonathon Sedgwick said: “AbbVie is committed to delivering transformative treatment options for patients suffering from autoimmune and fibrotic diseases. 

“We have seen strong progress in our current collaboration with Dragonfly focused on their triNKET technology and are pleased to expand our partnership to include additional immunology targets of interest to AbbVie.”

A clinical-stage biopharmaceutical firm, Dragonfly focuses on the discovery, development and marketing of therapeutics that leverage its TriNKET technology.

Dragonfly Therapeutics co-founder and CEO Bill Haney said: “We look forward to building on our successful collaboration, and rapidly progressing with the AbbVie team to advance new treatment options for patients.”

In August 2020, Dragonfly and Bristol Myers Squibb (BMS) entered a $475m agreement through which BMS obtained exclusive global licence to interleukin-12 (IL-12) investigational immunotherapy programme of the former.